Join the Oncology Voice Network. Join for Free
The Misalignment of Clinical Development and Field Medical Affairs
clinical development field medical affairs MSLs recruitment pharmaceutical strategies Boehringer Ingelheim

The Misalignment of Clinical Development and Field Medical Affairs


Share This Article


Summary

In this episode, Tom Caravela is joined by Carrie Caretta and Giancarlo Maranzano from Boehringer Ingelheim to explore the integration of clinical development and field medical affairs. They discuss the strategic role of field medical teams in clinical trial recruitment and how MSLs can effectively contribute to pipeline and asset development. The conversation covers best practices for hiring and training MSLs, evaluating their performance, and the metrics that define success. Carrie and Giancarlo emphasize the importance of collaboration within Medical Affairs and share insights on hiring MSLs early in the process. The episode concludes with reflections and appreciation for the listeners.

My guests today are Carrie Carretta, Executive Director, Clinical Development and Medical Affairs, and Giancarlo Maranzano, Team Leader Field Based Medicine at Boehringer Ingelheim and we discuss the misalignment in clinical development and Field Medical

Carrie and Giancarlo discuss…

👉 The gaps that exist between clinical and field medical

👉 What Pharma companies need to address strategically

👉 How MSLs can be better utilized in clinical development

👉 Ways field medical can be more innovative

👉 How MSLs can assist in the patient recruitment process

Click for Source
clinical development, field medical affairs, MSLs recruitment, pharmaceutical strategies, Boehringer Ingelheim

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
AI-powered real-world evidence: Strategically enhancing value and access
Partner Avatar Envision Pharma Group

AI-powered real-world evidence: Strategically enhancing value and access

Article
Clinical development success rates and social value of pediatric Phase 1 trials in oncology
OVN Avatar Mateusz T. Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora

Clinical development success rates and social value of pediatric Phase 1 trials in oncology

Article
Dose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming Recommendations
OVN Avatar Yassine Kamal Lyauk, Daniël Martijn Jonker, Trine Meldgaard Lund

Dose Finding in the Clinical Development of 60 US Food and Drug Administration-Approved Drugs Compared With Learning vs. Confirming Recommendations

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN